Search Results for: IT-27

Targeting Tools: Beta Products. Great Opportunity for Discovery at a Very Low Price.

News Tools /

Saporin conjugates specifically eliminate cells identified by an extracellular marker. Each week we release new products for beta testing, so check out the website frequently. There are two conjugate configurations for Beta products. The first is a direct conjugate of the targeting agent to saporin; the second is a bonded toxin between the targeting agent […]

Targeting Tools: Beta Products. Great Opportunity for Discovery at a Very Low Price. Read More »

Enhancing the therapeutic potential of extracellular vesicles using peptide technology

Martin Perez C, Conceição M, Raz R, Wood MJA, Roberts TC (2022) Enhancing the therapeutic potential of extracellular vesicles using peptide technology. (eds. Langel Ü). In: Cell Penetrating Peptides. Methods in Molecular Biology 2383:119-141. Humana, New York, NY. doi: 10.1007/978-1-0716-1752-6_8 Objective: To modify EVs with peptides which confer specific advantageous properties, thus enhancing their therapeutic

Enhancing the therapeutic potential of extracellular vesicles using peptide technology Read More »

Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation.

Li Z, Czechowicz A, Scheck A, Rossi DJ, Murphy PM (2019) Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation. Nat Commun 10:616. doi: 10.1038/s41467-018-08202-w Objective: To develop a conditioning protocol for fully MHC-mismatched bone marrow allotransplantation in mice involving transient immunosuppression and selective depletion of recipient hematopoietic stem

Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation. Read More »

Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.

Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes D, Tate T, Czechowicz A, Kfoury Y, Ruchika F, Rossi D, Verdine G, Mansour M, Scadden D (2016) Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol 34:738-745. doi: 10.1038/nbt.3584 Summary: To demonstrate correction of a clinically relevant disease, we employed

Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Read More »

Chemical strategies for antigen-selective targeting of autoreactive B Cells. Chapter 2: Sequential prodrug strategy to target and eliminate ACPA-selective autoreactive B cells.

Lelieveldt L (2019) Chemical strategies for antigen-selective targeting of autoreactive B Cells. Chapter 2: Sequential prodrug strategy to target and eliminate ACPA-selective autoreactive B cells. Radboud Universiteit Nijmegen Nijmegen, Netherlands 45-64. Thesis. Objective: To develop a method to target and selectively eliminate autoreactive B cells that produce anti-citrullinated proteins antibodies (ACPA) using a sequential antigen

Chemical strategies for antigen-selective targeting of autoreactive B Cells. Chapter 2: Sequential prodrug strategy to target and eliminate ACPA-selective autoreactive B cells. Read More »

Identification of lineage-specific markers for therapeutic targeting of mast cells.

Plum T (2019) Identification of lineage-specific markers for therapeutic targeting of mast cells. Ruperto-Carola University of Heidelberg, Germany Thesis. doi: 10.11588/heidok.00023555 Usage: Mice were injected i.v. with either 100 µg of 1:1 molar mixture of biotinylated CD63 antibody and Streptavidin-ZAP (60 µg mAb + 40 µg SAP) or with 40 µg SAP alone. All injections

Identification of lineage-specific markers for therapeutic targeting of mast cells. Read More »

Cover Article: Targeted depletion of hematopoietic stem cells promises safer transplantation

News Article /

By Rahul Palchaudhuri, Ph.D., Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA Hematopoietic stem cell transplantation (HSCT) has been clinically used for 58 years and offers life-saving therapies for a variety of malignant and non-malignant blood disorders. Currently 50,000 transplants are performed globally per year with 90% of these for the

Cover Article: Targeted depletion of hematopoietic stem cells promises safer transplantation Read More »

Search
Shopping Cart
Scroll to Top